Skip to main content
. 2016 Nov 2;3:16022. doi: 10.1038/mto.2016.22

Figure 4.

Figure 4

In vivo antitumor effects of polymer-coated virus on subcutaneous LL/2-CD46 tumors in preimmunized C57BL/6N mice. Immune-competent C57BL/6N mice were preimmunized with 1 × 106 TCID50 of MV-NPL. The mice were subsequently injected intratumorally with Tris-HCl (control), naked virus, or polymer-coated virus (coated virus) on days 1, 8, and 15 (a). Tumor volumes (mean ± SEM) were monitored for 9 female C57BL/6N mice, according to protocol A (b). CDC activities in the sera of mice injected with Tris-HCl (control), naked virus, or polymer-coated virus (coated virus) on days 1, 8, and 15 using protocol A are shown as the cell viability (c). Preimmunized mice were intratumorally injected with 1 × 105 TCID50, 2.5 × 105 TCID50, or 5 × 105 TCID50 of polymer-coated virus on days 1, 8, and 15 (d). Tumor volumes (mean ± SEM) were monitored in 5 female C57BL/6N mice, according to protocol B (e). CDC activities in the sera of mice treated according to protocol B were shown as the cell viability (f). NS, not significant; **P < 0.01; ***P < 0.001; ****P < 0.0001.